Price
No data yet.
Social Signal Score
Analyst Ratings
26 analystsRevenue
$256.15M+1079.04%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph K. Belanoff
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 730
- Beta
- 0.45
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 43.66
Financials
Revenue
$256.15M+1079.0%Net Income
$42.14M+1530.2%EBITDA
$46.79M+1412.9%Free Cash Flow
$31.02M+250.7%EPS (diluted)
$0.36+1700.0%Shares Outstanding (diluted)
118.39M+1.7%Operating Expenses
$210.79MCash & Debt
$308.20MReturn of Capital
$11.46MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $761.41M | $99.65M | $0.95 |
| 2024 | $675.04M | $139.73M | $1.35 |
| 2023 | $482.38M | $106.14M | $1.02 |
| 2022 | $401.86M | $101.42M | $0.95 |
| 2021 | $365.98M | $112.51M | $0.97 |
| 2020 | $353.87M | $106.01M | $0.92 |
| 2019 | $306.49M | $94.18M | $0.82 |
| 2018 | $251.25M | $75.41M | $0.60 |
| 2017 | $159.20M | $129.12M | $1.14 |
| 2016 | $81.32M | $8.14M | $0.07 |
| 2015 | $50.29M | $-6.41M | $-0.06 |
| 2014 | $26.55M | $-31.38M | $-0.31 |
| 2013 | $10.36M | $-46.01M | $-0.46 |
| 2012 | $3.31M | $-38.05M | $-0.41 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.41
- Implied price
- $52.16
- Return from $116.23
- -14.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $25.93 — -77.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 25 | 31 | 37 | 43 | 49 |
|---|---|---|---|---|---|
| -2.0% | -28.5% | -25.4% | -22.7% | -20.3% | -18.2% |
| 3.0% | -24.9% | -21.6% | -18.8% | -16.3% | -14.1% |
| 8.0% | -21.2% | -17.8% | -14.8% | -12.2% | -9.9% |
| 13.0% | -17.6% | -14.0% | -10.9% | -8.1% | -5.7% |
| 18.0% | -13.9% | -10.2% | -6.9% | -4.1% | -1.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60+20.00%Social Signal Score
Mentions (8)
- News (RSS)investing·6d ago·Positive
Corcept Therapeutics options: a long strangle signals volatility bet ahead of 2027
View source ↗ - Newszacks.com·19d ago·Positive
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026? Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
View source ↗ - Newsfxempire.com·20d ago·Positive
Corcept Grows to Mid-Cap on Institutional Support Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.
View source ↗ - News (Marketaux)seekingalpha.com·27d ago·Positive
Corcept Stock: Not Cheap, But Backed By Real Structural Growth (NASDAQ:CORT) The way I see it, Corcept T[+141 characters]
View source ↗ - Newszacks.com·38d ago·Neutral
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report? Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (RSS)seekingalpha·46d ago·Neutral
Like The Knick's, Corcept Rebounded And Is Crushing It
View source ↗ - Newsseekingalpha.com·46d ago·Positive
Like The Knick's, Corcept Rebounded And Is Crushing It Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.
View source ↗ - Newsfinbold.com·49d ago·Neutral
Trump is up 230% on this stock trade since March President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.81 per share
Typical surprise -11.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$0.36 vs $0.02beat
- Thu, Apr 30$-0.30 vs $-0.11miss
- Tue, Feb 24$0.20 vs $0.33miss
- Tue, Nov 4$0.16 vs $0.18miss
- Thu, Jul 31$0.29 vs $0.23beat
- Mon, May 5$0.17 vs $0.17beat
Estimates and results for CORT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CORT officers and directors.
- Bought
- —
- Sold
- $47.8m
0 trades
47 trades
- Vieira Roberto Wandenkolksold
- Wilson James Nsold
- Wilson James Nsold
- Wilson James Nsold
- Lyon Joseph Douglassold
- Lyon Joseph Douglassold
- Vieira Roberto Wandenkolksold
- Vieira Roberto Wandenkolksold
53 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CORT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.